SCHEMBL8091809

SCHEMBL8091809

CC1CCN(c2ccccn2)C1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRM1 Q13255 5/20 0.51
PLD1 Q13393 1/20 0.50
GPR119 Q8TDV5 2/20 0.48
PDE10A Q9Y233 1/20 0.47
AVPR1A P37288 2/20 0.47
KDM4E B2RXH2 1/20 0.46
ALDH1A1 P00352 1/20 0.46
MAPT P10636 1/20 0.46
GRIN2D O15399 1/20 0.46
GRIN3B O60391 1/20 0.46
GRIN1 Q05586 1/20 0.46
GRIN2A Q12879 1/20 0.46
GRIN2B Q13224 1/20 0.46
GRIN2C Q14957 1/20 0.46
GRIN3A Q8TCU5 1/20 0.46
USP30 Q70CQ3 1/20 0.46
MEN1 O00255 1/20 0.46
PKM P14618 1/20 0.46
TSHR P16473 1/20 0.46
KMT2A Q03164 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23875675 1.00 GRM1 (0.51) GRM1PLD1GPR119PDE10AAVPR1A
SCHEMBL13572999 0.90 GRM1 (0.52) GRM1PLD1KDM4EALDH1A1MAPT
SCHEMBL19844773 0.90 GRM1 (0.52) GRM1PLD1KDM4EALDH1A1MAPT
SCHEMBL19844779 0.90 GRM1 (0.52) GRM1PLD1KDM4EALDH1A1MAPT
SCHEMBL29774590 0.89 PLD1 (0.58) PLD1GPR119AVPR1AKDM4EALDH1A1
SCHEMBL359401 0.89 PLD1 (0.58) PLD1GPR119AVPR1AKDM4EALDH1A1
Ammonia Solution, Strong SCHEMBL8126869 0.88 PLD1 (0.56) PLD1GPR119AVPR1AKDM4EALDH1A1
SCHEMBL23875353 0.85 PLD1 (0.52) GRM1PLD1KDM4EALDH1A1MAPT
SCHEMBL29991351 0.82 GRIN2B (0.49) GRM1PLD1KDM4EALDH1A1MAPT
SCHEMBL24548016 0.82 GRM1 (0.48) GRM1PLD1GPR119AVPR1AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3856735-B1 FUSED BICYCLIC HETEROCYCLES AS THERAPEUTIC AGENTS UNIV NEW YORK (US) 2023-09-06 EP disclosed
WO-2021194878-A1 SELECTIVE MODULATORS OF MUTANT LRRK2 PROTEOLYSIS AND ASSOCIATED METHODS OF USE ARVINAS OPERATIONS, INC. (US) 2021-09-30 WO disclosed
EP-3193604-B1 SUBSTITUTED N-(PYRROLIDIN-3-YL)ISOXAZOLE-3-CARBOXAMIDE COMPOUNDS EPIZYME INC (US) 2021-06-16 EP disclosed
EP-3689868-A1 TETRAHYDRONAPHTHALENE AND TETRAHYDROISOQUINOLINE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS Arvinas Operations, Inc. (US) 2020-08-05 EP disclosed
WO-2016044792-A1 INHIBITING THE TRANSIENT RECEPTOR POTENTIAL A1 ION CHANNEL HYDRA BIOSCIENCES, INC. (US) 2016-03-24 WO disclosed
EP-2203459-B1 SPIROCYCLIC AMINOQUINOLONES AS GSK-3 INHIBITORS KYORIN SEIYAKU KK (JP) 2016-03-16 EP disclosed
US-9199946-B2 Pyrimidinone carboxamide inhibitors of endothelial lipase BRISTOL-MYERS SQUIBB COMPANY (US) 2015-12-01 US disclosed
US-20150065505-A1 PYRIMIDINONE CARBOXAMIDE INHIBITORS OF ENDOTHELIAL LIPASE BRISTOL-MYERS SQUIBB COMPANY (US) 2015-03-05 US disclosed
US-8901112-B2 Spirocyclic aminoquinolones as GSK-3 inhibitors KYORIN PHARMACEUTICAL CO., LTD. (JP) 2014-12-02 US disclosed
US-8901112-B2 Spirocyclic aminoquinolones as GSK-3 inhibitors KYORIN PHARMACEUTICAL CO., LTD. (JP) 2014-12-02 US disclosed
US-5084509-A Peptides or proteins bound to aminoalkyl polydimethylacrylamide for immunology BAYLOR COLLEGE OF MEDICINE (US) 1992-01-28 US disclosed
US-5028675-A Polyamide resin and method for preparation of reagents for immunodiagn ostic use SOUTHWEST FOUNDATION FOR BIOMEDICAL RESEARCH (US) 1991-07-02 US disclosed
WO-1990015627-A1 METHODS AND COMPOSITIONS FOR THE PREPARATION AND USE OF SITE-DIRECTED IMMUNOLOGIC REAGENTS BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 1990-12-27 WO disclosed
US-4973638-A DIMETHYLACRYLAMIDE, N-ACRYLYL DIAMINOALKANE, CROSSLINKER, AND EMULSIFIER SOUTHWEST FOUNDATION FOR BIOMEDICAL RESEARCHE (US) 1990-11-27 US disclosed
EP-0276279-A4 COMPOSITION OF MATTER AND METHOD OF IMMUNIZING AGAINST VIRAL CAUSATIVE AGENTS OF AIDS AND ARC. SOUTHWEST FOUND BIOMED RES (US) 1990-01-08 EP disclosed
EP-0265501-A4 POLYAMIDE RESIN AND METHOD FOR PREPARATION OF REAGENTS FOR IMMUNODIAGNOSTIC USE. SOUTHWEST FOUND BIOMED RES (US) 1988-11-09 EP disclosed
EP-0276279-A1 COMPOSITION OF MATTER AND METHOD OF IMMUNIZING AGAINST VIRAL CAUSATIVE AGENTS OF AIDS AND ARC SOUTHWEST FOUNDATION FOR BIOMEDICAL RESEARCH (US) 1988-08-03 EP disclosed
EP-0265501-A1 POLYAMIDE RESIN AND METHOD FOR PREPARATION OF REAGENTS FOR IMMUNODIAGNOSTIC USE SOUTHWEST FOUNDATION FOR BIOMEDICAL RESEARCH (US) 1988-05-04 EP disclosed
WO-1988000471-A1 COMPOSITION OF MATTER AND METHOD OF IMMUNIZING AGAINST VIRAL CAUSATIVE AGENTS OF AIDS AND ARC SOUTHWEST FOUNDATION FOR BIOMEDICAL RESEARCH (US) 1988-01-28 WO disclosed
WO-1987006594-A1 POLYAMIDE RESIN AND METHOD FOR PREPARATION OF REAGENTS FOR IMMUNODIAGNOSTIC USE SOUTHWEST FOUNDATION FOR BIOMEDICAL RESEARCH (US) 1987-11-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150065505-A1 PYRIMIDINONE CARBOXAMIDE INHIBITORS OF ENDOTHELIAL LIPASE LIPG, LPL, PNLIP GRM1 2782/4885PLD1 152/4885GPR119 59/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.